

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of: David Jonathan Madge et al.

Filed: September 9, 2003 Confirmation No.: 7469

BORONIC ACID SALTS

pplication No.: 10/659,178

Examiner: To be assigned

Art Unit: 1621

Attorney Reference No.: 6613-66750-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Date Mailed _ January 24, 2006

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- 冈 Supplemental Information Disclosure Statement PTO-1449 Form and a copy of a Non-U.S. Reference listed thereon
- M The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- \boxtimes Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Registration No. 34,420

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David Jonathan Madge et al.

Application No.: 10/659,178

Filed: September 9, 2003 Confirmation No.: 7469

For: BORONIC ACID SALTS

Examiner: To be assigned

Art Unit: 1621

Attorney Reference No.: 6613-66750-01



CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed January 24, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 are two English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. A copy of the non-U.S. reference is enclosed herewith.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Wayne W. Rupert

Registration No. 34,420

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

			Application Number			10/659,178		
HYPORY	MATION	FATEMENT	Filing Da	te		September 9, 2003		
	•	BY APPLICANT		First Named Inventor			David Jonathan Madge	
			Art Unit			1621		
JAN 2 6 20	(بع 16		Examiner Name			To be assigned		
Xaminer's		τ	J.S. PATENT I	OCUMEN	TS			
Examiner's Initials*	Cite No. (optional)	Number Public		tion Date Name of		ne of A	Applicant or Patentee	
		5,639,739	17 June 1997		Dominguez et al.			
	r	FOF	REIGN PATEN	T DOCUM	IENTS			
xaminer's Initials*	Cite No. (optional)	Country	untry Number		Publication Date		Name of Applicant or Patentee	
xaminer's Initials*	Cite No. (optional)	OTHER DOCUMENTS						
		Berge et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences 66(1):1-19, 1977						
								
								
	<u> </u>			DATE				
XAMINEI IGNATUR				CONSIDERED:				

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not

in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number

6613-66750-01